Literature DB >> 22012861

Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia.

T Gaszynski1, T Szewczyk, W Gaszynski.   

Abstract

BACKGROUND: Complete and fast recovery of neuromuscular function is very important in morbidly obese patients because of the possible influence of postoperative residual curarization (PORC) on respiratory function in the postoperative period. Recent reports underline incidences of the residual influence of neuromuscular blocking agents.
METHODS: Seventy morbidly obese (BMI >40 kg m(-2)) patients requiring general anaesthesia and receiving rocuronium for muscle relaxation were randomly assigned into two groups: at the end of the anaesthetic procedure, one group received sugammadex 2 mg kg(-1) of corrected body weight (Group SUG) and the other group received neostigmine 0.05 mg kg(-1) of CBW (Group NEO). At the end of surgery and when response reached a train-of-four (TOF) score of 2, patients received the study drugs. The neuromuscular function was recorded and time to achieve 90% of TOF (safe extubation) was measured. Patients were examined directly after arrival to the post-anaesthesia care unit (PACU) by a blinded investigator for the presence of PORC.
RESULTS: Thirty-five patients received sugammadex and 35 neostigmine. Mean dose of rocuronium was 87.9 vs 85.6 mg (P>0.05), mean time to 90% of TOF was 2.7 vs 9.6 min (P<0.05), and TOF at the PACU was 109.8% vs 85.5% (P<0.05) in Groups SUG and NEO, respectively.
CONCLUSIONS: Administration of sugammadex provides fast recovery of neuromuscular function and prevents PORC in the morbidly obese, however neostigmine does not.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012861     DOI: 10.1093/bja/aer330

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  28 in total

1.  [Modified rapid sequence induction for Caesarian sections : case series on the use of rocuronium and sugammadex].

Authors:  D Nauheimer; C Kollath; G Geldner
Journal:  Anaesthesist       Date:  2012-08       Impact factor: 1.041

2.  Sugammadex: An Update.

Authors:  Tiberiu Ezri; Mona Boaz; Alexander Sherman; Marwan Armaly; Yitzhak Berlovitz
Journal:  J Crit Care Med (Targu Mures)       Date:  2016-02-09

Review 3.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.

Authors:  Ana-Marija Hristovska; Patricia Duch; Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2017-08-14

4.  Repeated sugammadex usage in a patient with multiple sclerosis: a case report.

Authors:  Nadir Sinikoglu; Tolga Totoz; Funda Gumus; Onur Karagulle
Journal:  Wien Klin Wochenschr       Date:  2015-01-14       Impact factor: 1.704

5.  Sugammadex.

Authors:  Dennis J Cada; Terri L Levien; Danial E Baker
Journal:  Hosp Pharm       Date:  2016-07

6.  Respiratory events with sugammadex vs. neostigmine following laparoscopic sleeve gastrectomy: a prospective pilot study assessing neuromuscular reversal strategies.

Authors:  Shmuel Evron; Yuri Abelansky; Tiberiu Ezri; Alexander Izakson
Journal:  Rom J Anaesth Intensive Care       Date:  2017-10

7.  Residual Paralysis: Does it Influence Outcome After Ambulatory Surgery?

Authors:  Hassan Farhan; Ingrid Moreno-Duarte; Duncan McLean; Matthias Eikermann
Journal:  Curr Anesthesiol Rep       Date:  2014-12

8.  Anesthetic Pharmacology and the Morbidly Obese Patient.

Authors:  Jerry Ingrande; Hendrikus Jm Lemmens
Journal:  Curr Anesthesiol Rep       Date:  2012-12-13

9.  Comparison of Sugammadex versus Neostigmine Costs and Respiratory Complications in Patients with Obstructive Sleep Apnoea.

Authors:  Dilek Yazıcıoğlu Ünal; İlkay Baran; Murad Mutlu; Gülçin Ural; Taylan Akkaya; Onur Özlü
Journal:  Turk J Anaesthesiol Reanim       Date:  2015-12-01

10.  Sugammadex allows fast-track bariatric surgery.

Authors:  Michele Carron; Stefano Veronese; Mirto Foletto; Carlo Ori
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.